Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine plus prolonged exposure psychotherapy for PTSD
ACTRN12625000722493Phase 2Not yet recruiting
- Sponsor
- University of Otago
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in post-traumatic stress disorder (PTSD), sponsored by University of Otago. Primary endpoints: Anxiety and Suicidality. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12625000722493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000722493.